Search clinical trials for: ACT001

Total 285 results

Abyss Ingredients
Eurofins

Recruiting

Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms

Eczema | Atopic Dermatitis

Spain
Accendatech USA Inc.
Avance Clinical Pty Ltd.; C3 Research Associates

Recruiting

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Recurrent Glioblastoma Multiforme(GBM)

United States
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Avotres Inc.

Active, not recruiting

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Promius Pharma, LLC

Completed

ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis

Actinic Keratosis

United States
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Sinocelltech Ltd.

Unknown

The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care

Covid19
Coegin Pharma AB
Bispebjerg Hospital; Studies&Me

Active, not recruiting

Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK (COAKS)

Actinic Keratoses

Denmark
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai Public Health Clinical Center

Active, not recruiting

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

Renal Cell Carcinoma

China
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
AiViva BioPharma, Inc.

Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Papulopustular Rosacea

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Massachusetts General Hospital

Recruiting

AT1001 for the Treatment of COVID-19 Related MIS-C

Covid19 | Multisystem Inflammatory Syndrome in Children

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis (FREEDOM-3)

Diffuse Cutaneous Systemic Sclerosis

United States
Shanghai Zhongshan Hospital
Transcenta Holding Limited

Completed

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

China
Blue Note Therapeutics
Durham VA Health Care System

Terminated

BNT001 Digital Therapeutic Feasibility Pilot Study

Cancer

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Gastric Cancer | Pancreatic Cancer

United States, Canada
Basilea Pharmaceutica

Completed

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Fungal Infection

United Kingdom
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients (FREEDOM-2)

Kidney Transplantation

United States
Adrian Hernandez
Massachusetts General Hospital; Mayo Clinic; National Heart, Lung, and Blood... and other collaborators

Completed

Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF)

Heart Failure

United States
Lifecells, LLC.

Completed

Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia (CLI)

Critical Limb Ischemia

United States
Cessatech A/S

Not yet recruiting

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

Pain
AJNA Australia Pty Ltd

Not yet recruiting

A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Healthy Volunteers
AriBio Co., Ltd.

Recruiting

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Alzheimer Disease

Korea, Republic of, United States, United Kingdom
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
AriBio Co., Ltd.

Completed

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Mild to Moderate Alzheimer's Disease

United States
XyloCor Therapeutics, Inc.

Completed

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) (EXACT)

Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Artery Disease | Angina Refractory

United States
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
Amicus Therapeutics

Active, not recruiting

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Fabry Disease

United States, United Kingdom
Amicus Therapeutics

Completed

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Fabry Disease

United States
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Pinteon Therapeutics, Inc
United States Department of Defense

Terminated

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Traumatic Brain Injury

United States
Aires Pharmaceuticals, Inc.

Terminated

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

Pulmonary Arterial Hypertension

United States, Australia, Hungary
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States

3

Subscribe